Literature DB >> 27307426

Bilateral adrenal myelolipoma in Cushing's disease: a relook into the role of corticotropin in adrenal tumourigenesis.

Partha Pratim Chakraborty1, Rana Bhattacharjee2, Pradip Mukhopadhyay2, Subhankar Chowdhury2.   

Abstract

Adrenal myelolipomas are infrequently encountered benign tumours of unknown aetiology. In the majority of cases they are unilateral, and clinically and hormonally silent, only requiring periodic follow-up. However, bilateral adrenal myelolipomas are sometimes associated with endocrine disorders and warrant appropriate evaluation. Though the understanding of the pathophysiology of adrenal myelolipomas has long been elusive, adrenocorticotropic hormone (ACTH) has been proposed as the main tropic factor in a number of studies. Cushing's disease is rarely associated with bilateral and sometimes giant myelolipomas. In this article, the association of bilateral adrenal myelolipomas with Cushing's disease has been discussed and the role of ACTH in the tumourigenesis has been reviewed. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27307426      PMCID: PMC4932459          DOI: 10.1136/bcr-2016-214965

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  8 in total

1.  Hormonally induced transformation of adrenal into myeloid tissue.

Authors:  H SELYE; H STONE
Journal:  Am J Pathol       Date:  1950-03       Impact factor: 4.307

2.  Adrenocorticotrophin-independent unilateral macronodular adrenal hyperplasia occurring with myelolipoma: an unusual cause of Cushing's syndrome.

Authors:  P J Jenkins; S L Chew; D G Lowe; R H Reznek; J A Wass
Journal:  Clin Endocrinol (Oxf)       Date:  1994-12       Impact factor: 3.478

3.  Adrenal myelolipoma associated with Cushing's disease.

Authors:  B D Bennett; T J McKenna; A J Hough; R Dean; D L Page
Journal:  Am J Clin Pathol       Date:  1980-03       Impact factor: 2.493

4.  Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia.

Authors:  Estelle Louiset; Céline Duparc; Jacques Young; Sylvie Renouf; Milène Tetsi Nomigni; Isabelle Boutelet; Rossella Libé; Zakariae Bram; Lionel Groussin; Philippe Caron; Antoine Tabarin; Fabienne Grunenberger; Sophie Christin-Maitre; Xavier Bertagna; Jean-Marc Kuhn; Youssef Anouar; Jérôme Bertherat; Hervé Lefebvre
Journal:  N Engl J Med       Date:  2013-11-28       Impact factor: 91.245

5.  Adrenal myelolipoma: diagnosis and management.

Authors:  Siamak Daneshmand; Marcus L Quek
Journal:  Urol J       Date:  2006       Impact factor: 1.510

6.  Lack of ACTH and androgen receptor expression in a giant adrenal myelolipoma associated with 21-hydroxylase deficiency.

Authors:  Hanae Hagiwara; Takeshi Usui; Takashi Kimura; Tetsuya Tagami; Mitsuhide Naruse; Sachiko Minamiguchi; Takuma Kato; Hiroshi Okuno; Akira Shimatsu
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

Review 7.  CT and MR imaging of the adrenal glands in ACTH-independent cushing syndrome.

Authors:  Andrea G Rockall; Syed A Babar; S A Aslam Sohaib; Andrea M Isidori; Salvador Diaz-Cano; John P Monson; Ashley B Grossman; Rodney H Reznek
Journal:  Radiographics       Date:  2004 Mar-Apr       Impact factor: 5.333

8.  Giant bilateral adrenal myelolipoma with congenital adrenal hyperplasia.

Authors:  S Al-Bahri; A Tariq; B Lowentritt; D V Nasrallah
Journal:  Case Rep Surg       Date:  2014-07-16
  8 in total
  2 in total

1.  Experience of a Tertiary-Level Urology Center in Clinical Urological Events of Rare and Very Rare Incidence. V. Urological Tumors: 1. Adrenal Myelolipoma.

Authors:  Rabea A Gadelkareem; Ahmed M Moeen; Mahmoud Khalil; Ahmed Reda; Mahmoud Farouk; Islam F Abdelkawi; Rania Makboul; Nasreldin Mohammed; Dia A Hameed
Journal:  Curr Urol       Date:  2020-06-23

2.  Case report of a bilateral adrenal myelolipoma associated with Cushing disease.

Authors:  Se Yoon Park; Mi Kyung Kwak; Hye Jeong Kim; Hyeong Kyu Park; Kyo-Il Suh; Myung Hi Yoo; So Young Jin; Sumi Yun; Dong Won Byun
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.